Stocks · News reference

Moleculin Biotech Announces Preclinical Data Showing Annamycin Antitumor Activity In Pancreatic Cancer Is Immune-Mediated

Sep 25, 2026, 5:06 PMBenzinga Newsdesk

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Sep 25, 2026, 5:06 PM
Checked: Sep 25, 2026, 5:06 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaOct 20, 2026, 7:26 PMBenzinga Newsdesk
Moleculin Biotech shares are trading higher after the company highlighted progress in its Phase 2/3 MIRACLE trial of Annamycin, including completed Part A enrollment and encouraging interim efficacy results.
MBRX
SEC EDGAROct 20, 2026, 11:00 AMSEC EDGAR
8-K filing — Moleculin Biotech, Inc. (MBRX)
Filed: 2026-10-20 AccNo: 0001437749-26-032969 Size: 313 KB Item 3.03: Material Modifications to Rights of Security Holders Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
MBRX
BenzingaOct 16, 2026, 1:50 PMBenzinga Newsdesk
Moleculin Biotech shares are trading lower after the company announced a 1-for-20 reverse stock split, effective October 20.
MBRX
BenzingaOct 16, 2026, 1:21 PMBenzinga Newsdesk
Moleculin Biotech Announces 1-For-20 Reverse Stock Split, Effective October 20
MBRX